InnoCare Pharmaceuticals (HKEX: 09969), after successfully dosing the first patient in a Phase 2 trial of ICP-192 for urothelial cancer, today announced the first patient dosed in a Phase 2 clinical trial of ICP-192 in patients with cholangiocarcinoma. ICP-192 is a potentially best-in-class highly selective small-molecule pan-FGFR inhibitor for the treatment of various solid tumors with FGFR aberrations. ICP-192 is currently undergoing Phase 1/2 studies in China and the United States.
The Phase 2 multi-center, single-arm, open-label clinical trial is designed to evaluate the safety and efficacy of ICP-192 in patients with advanced cholangiocarcinoma that have FGFR aberrations in China.
“FGFR aberrations have been found in a variety of cancers, including cholangiocarcinoma, urothelial cancer, epithelial cancer, breast cancer, and many others. This clinical study has the potential to provide a better treatment option to all patients with FGFR aberrations, ” said Dr. Li Jin of the Shanghai East Hospital.
“We will continue to advance ICP-192 in clinical trials for the treatment of advanced solid tumors with FGFR aberrations both in China and globally,” said Dr. Jisong Cui, Co-founder, Chairman, and CEO of InnoCare. “We have successfully dosed the first patients for urothelial cancer and cholangiocarcinoma. InnoCare will continue to work with top researchers to explore the use of ICP-192 for a variety of solid tumors, so that we may provide patients with superior treatment options.”
About InnoCare Pharma
InnoCare Pharmaceuticals is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high incidence rates in the Chinese population. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.